Investigation of the use of antioxidants to diminish the adverse effects of postnatal glucocorticoid treatment on mortality and cardiac development

Neonatology

Volumn 98, Issue 1, 2010, Pages 73-83

  Adler, Alexandra ^a   Camm, Emily J ^a   Hansell, Jeremy A ^a   Richter, Hans G ^a   Giussani, Dino A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Glucocorticoids; Oxidative stress; Prematurity

Indexed keywords

4 HYDROXYNONENAL; ALPHA TOCOPHEROL; ASCORBIC ACID; BIOLOGICAL MARKER; DEXAMETHASONE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEAT SHOCK PROTEIN 90; SODIUM CHLORIDE; 4-HYDROXY-2-NONENAL; ALDEHYDE; ANTIOXIDANT; GLUCOCORTICOID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTERY DIAMETER; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG POTENTIATION; FEMALE; GROWTH RETARDATION; HEART DEVELOPMENT; HEART LEFT VENTRICLE VOLUME; HEART VENTRICLE WALL; MALE; MORTALITY; NEWBORN; NONHUMAN; OXIDATIVE STRESS; PREMATURITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STEREOLOGY; SURVIVAL; THORACIC AORTA; WESTERN BLOTTING; ANIMAL; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; CHRONIC DISEASE; DRUG COMBINATION; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HEART; LUNG DISEASES;

ALDEHYDES; ANIMALS; ANIMALS, NEWBORN; ANTIOXIDANTS; ASCORBIC ACID; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DEXAMETHASONE; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HEART; HSP90 HEAT-SHOCK PROTEINS; LUNG DISEASES; MALE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; RATS; VITAMIN E;

ANIMALIA; RATTUS;

EID: 73649085207     PISSN: 16617800     EISSN: 16617819     Source Type: Journal    
DOI: 10.1159/000275561     Document Type: Article

References (58)

1. Kinsella JP, Greenough A, Abman SH: Bronchopulmonary dysplasia. Lancet 2006; 367: 1421-1431.
2. Northway WH Jr, Rosan RC, Porter DY: Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 1967; 276: 357-368.
3. Fanaroff AA, Stoll BJ, Wright LL, Carlo WA, Ehrenkranz RA, Stark AR, Bauer CR, Donovan EF, Korones SB, Laptook AR, Lemons JA, Oh W, Papile LA, Shankaran S, Stevenson DK, Tyson JE, Poole WK: Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol 2007; 196: 147.e1-147.e8.
4. Cummings JJ, D'Eugenio DB, Gross SJ: A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med 1989; 320: 1505-1510.
5. Halliday HL, Ehrenkranz RA, Doyle LW: Early ( ! 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2009: CD001146.
6. Halliday HL, Ehrenkranz RA, Doyle LW: Late ( 1 7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2009:CD001145.
7. Ballard PL, Ballard RA: Scientific basis and therapeutic regimens for use of antenatal glucocorticoids. Am J Obstet Gynecol 1995; 173: 254-262.
8. Liggins GC: Fetal lung maturation. Aust NZ J Obstet Gynaecol 1994; 34: 247-250.
9. Stark AR, Carlo WA, Tyson JE, Papile LA, Wright LL, Shankaran S, Donovan EF, Oh W, Bauer CR, Saha S, Poole WK, Stoll BJ: Adverse effects of early dexamethasone in extremely- low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 2001; 344: 95-101.
10. Thorp JA, Jones PG, Peabody JL, Knox E, Clark RH: Effect of antenatal and postnatal corticosteroid therapy on weight gain and head circumference growth in the nursery. Obstet Gynecol 2002; 99: 109-115.
11. Yeh TF, Lin YJ, Huang CC, Chen YJ, Lin CH, Lin HC, Hsieh WS, Lien YJ: Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics 1998; 101:E7.
12. Yeh TF, Lin YJ, Lin HC, Huang CC, Hsieh WS, Lin CH, Tsai CH: Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 2004; 350: 1304-1313.
13. Flagel SB, Vazquez DM, Watson Jr. SJ, Neal Jr. CR: Effects of tapering neonatal dexamethasone on rat growth, neurodevelopment, and stress response. Am J Physiol 2002; 282:R55-R63.
14. He J, Varma A, Weissfeld LA, Devaskar SU: Postnatal glucocorticoid exposure alters the adult phenotype. Am J Physiol 2004; 287: R198-208.
15. Neal Jr. CR, Weidemann G, Kabbaj M, Vazquez DM: Effect of neonatal dexamethasone exposure on growth and neurological development in the adult rat. Am J Physiol l 2004; 287:R375-R385.
16. Bensky AS, Kothadia JM, Covitz W: Cardiac effects of dexamethasone in very low birth weight infants. Pediatrics 1996; 97: 818-821.
17. Ohning BL, Fyfe DA, Riedel PA: Reversible obstructive hypertrophic cardiomyopathy after dexamethasone therapy for bronchopulmonary dysplasia. Am Heart J 1993; 125: 253-256.
18. Werner JC, Sicard RE, Hansen TW, Solomon E, Cowett RM, Oh W: Hypertrophic cardiomyopathy associated with dexamethasone therapy for bronchopulmonary dysplasia. J Pediatr 1992; 120: 286-291.
19. De Vries WB, Bal MP, Homoet-van Der Kraak P, Kamphuis PJ, van Der Leij FR, Baan J, Steendijk P, de Weger RA, van Bel F, van Oosterhout MF: Suppression of physiological cardiomyocyte proliferation in the rat pup after neonatal glucocorticosteroid treatment. Basic Res Cardiol 2006; 101: 36-42.
20. Li F, Wang X, Capasso JM, Gerdes AM: Rapid transition of cardiac myocytes from hyperplasia to hypertrophy during postnatal development. J Mol Cell Cardiol 1996; 28: 1737-1746.
21. De Vries WB, van Der Leij FR, Bakker JM, Kamphuis PJ, van Oosterhout MF, Schipper ME, Smid GB, Bartelds B, van Bel F: Alterations in adult rat heart after neonatal dexamethasone therapy. Pediatr Res 2002; 52: 900-906.
22. Bal MP, de Vries WB, van Der Leij FR, van Oosterhout MF, Berger RM, Baan J, van Der Wall EE, van Bel F, Steendijk P: Neonatal glucocorticosteroid treatment causes systolic dysfunction and compensatory dilation in early life: studies in 4-week-old prepubertal rats. Pediatr Res 2005; 58: 46-52.
23. Bal MP, de Vries WB, van Oosterhout MF, Baan J, van Der Wall EE, van Bel F, Steendijk P: Long-term cardiovascular effects of neonatal dexamethasone treatment: hemodynamic follow-up by left ventricular pressurevolume loops in rats. J Appl Physiol 2008; 104: 446-450.
24. American Academy of Pediatrics: Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 2002; 109: 330-338.
25. Grier DG, Halliday HL: Management of bronchopulmonary dysplasia in infants: guidelines for corticosteroid use. Drugs 2005; 65: 15-29.
26. Baden M, Bauer CR, Colle E, Klein G, Taeusch HW, Stern L: A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. Pediatrics 1972; 50: 526-534.
27. Rademaker KJ, de Vries LS, Uiterwaal CS, Groenendaal F, Grobbee DE, van Bel F: Postnatal hydrocortisone treatment for chronic lung disease in the preterm newborn and long-term neurodevelopmental follow-up. Arch Dis Child Fetal Neonatal 2008; 93:F58-F63.
28. Iuchi T, Akaike M, Mitsui T, Ohshima Y, Shintani Y, Azuma H, Matsumoto T: Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. Circ Res 2003; 92: 81-87.
29. Rajashree S, Puvanakrishnan R: Dexamethasone induced alterations in enzymatic and nonenzymatic antioxidant status in heart and kidney of rats. Mol Cell Biochem 1998; 181: 77-85.
30. Whitworth JA, Schyvens CG, Zhang Y, Andrews MC, Mangos GJ, Kelly JJ: The nitric oxide system in glucocorticoid-induced hypertension. J Hypertens 2002; 20: 1035-1043.
31. Zhang Y, Croft KD, Mori TA, Schyvens CG, McKenzie KU, Whitworth JA: The antioxidant tempol prevents and partially reverses dexamethasone-induced hypertension in the rat. Am J Hypertens 2004; 17: 260-265.
32. Cai H, Harrison DG: Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-844.
33. Hamilton CA, Miller WH, Al-Benna S, Brosnan MJ, Drummond RD, McBride MW, Dominiczak AF: Strategies to reduce oxidative stress in cardiovascular disease. Clin Sci (Lond) 2004; 106: 219-234.
34. Li JM, Shah AM: Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am J Physiol 2004; 287:R1014-R1030.
35. Oncu M, Gultekin F, Karaöz E, Altuntas I, Delibas N: Nephrotoxicity in rats induced by chlorpryfos-ethyl and ameliorating effects of antioxidants. Hum Exp Toxicol 2007; 21: 223-230.
36. Burton GW: Vitamin E: molecular and biological function. Proc Nutr Soc 1994; 53: 251-262.
37. Carr AC, Zhu BZ, Frei B: Potential antiatherogenic mechanisms of ascorbate (vitamin C) and - -tocopherol (vitamin E). Circ Res 2000; 87: 349-354.
38. Jackson TS, Xu A, Vita JA, Keaney Jr. JF: Ascorbate prevents the interaction of superoxide and nitric oxide only at very high physiological concentrations. Circ Res 1998; 83: 916-922.
39. Burton GJ, Palmer ME: Eradicating fetomaternal fluid shift during perfusion fixation of the human placenta. Placenta 1988; 9: 327-332.
40. Gundersen HJG, Bendtsen TF, Korbo L, Marcussen N, Moller A, Nielsen K, Nyengaard JR, Pakkenberg B, Sorensen FB, Vesterby A, West MJ: Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS 1988; 96: 379-394.
41. Jensen EB, Gundersen HJG, Osterby R: Determination of membrane thickness distribution from orthogonal intercepts. J Microsc 1979; 115: 19-33.
42. Sicard RE, Werner JC: Dexamethasone induces a transient relative cardiomegaly in neonatal rats. Pediatr Res 1992; 31: 359-363.
43. Thibeault DW, Heimes B, Rezaiekhaligh M, Mabry S: Chronic modifications of lung and heart development in glucocorticoid-treated newborn rats exposed to hyperoxia or room air. Pediatr Pulmonol 1993; 16: 81-88.
44. Daniels VG, Hardy RN, Malinowska KW, Nathanielsz PW: The influence of exogenous steroids on macromolecule uptake by the small intestine of the newborn rat. J Physiol 1973; 229: 681-695.
45. Weiler HA, Wang Z, Atkinson SA: Whole body lean mass is altered by dexamethasone treatment through reductions in protein and energy utilization in piglets. Biol Neonate 1997; 71: 53-59.
46. Bendich A, Gabriel E, Machlin LJ: Dietary vitamin E requirement for optimum immune responses in the rat. J Nutr 1986; 116: 675-681.
47. Poli G, Biasi F, Leonarduzzi G: 4-Hydroxynonenal- protein adducts: a reliable biomarker of lipid oxidation in liver diseases. Mol Aspects Med 2008; 29: 67-71.
48. Schafer SC, Wallerath T, Closs EI, Schmidt C, Schwarz PM, Forstermann U, Lehr HA: Dexamethasone suppresses eNOS and CAT-1 and induces oxidative stress in mouse resistance arterioles. Am J Physiol 2005; 288: H436-H444.
49. Cai S, Alp NJ, McDonald D, Smith I, Kay J, Canevari L, Heales S, Channon KM: GTP cyclohydrolase I gene transfer augments intracellular tetrahydrobiopterin in human endothelial cells: effects on nitric oxide synthase activity, protein levels and dimerisation. Cardiovasc Res 2002; 55: 838-849.
50. Wallerath T, Witte K, Schafer SC, Schwarz PM, Prellwitz W, Wohlfart P, Kleinert H, Lehr HA, Lemmer B, Forstermann U: Downregulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid- mediated hypertension. Proc Natl Acad Sci USA 1999; 96: 13357-13362.
51. Whitsett J, Picklo MJ Sr, Vasquez-Vivar J: 4- Hydroxy-2-nonenal increases superoxide anion radical in endothelial cells via stimulated GTP cyclohydrolase proteasomal degradation. Arterioscler Thromb Vasc Biol 2007; 27: 2340-2347.
52. Huang A, Vita JA, Venema RC, Keaney Jr. JF: Ascorbic acid enhances endothelial nitricoxide synthase activity by increasing intracellular tetrahydrobiopterin. J Biol Chem 2000; 275: 17399-17406.
53. Munzel T, Harrison DG: Increased superoxide in heart failure: a biochemical baroreflex gone awry. Circulation 1999; 100: 216-218.
54. Derks JB, Giussani DA, Jenkins SL, Wentworth RA, Visser GH, Padbury JF, Nathanielsz PW: A comparative study of cardiovascular, endocrine and behavioural effects of betamethasone and dexamethasone administration to fetal sheep. J Physiol 1997; 499: 217-226.
55. Fletcher AJ, McGarrigle HH, Edwards CM, Fowden AL, Giussani DA: Effects of low dose dexamethasone treatment on basal cardiovascular and endocrine function in fetal sheep during late gestation. J Physiol 2002; 545: 649-660.
56. Bjelakovic G, Nikolova D, Gluud L, Simonetti R, Gluud C: Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev 2008:CD007176.
57. Daghini E, Chade AR, Krier JD, Versari D, Lerman A, Lerman LO: Acute inhibition of the endogenous xanthine oxidase improves renal hemodynamics in hypercholesterolemic pigs. Am J Physiol 2006; 290:R609-R615.
58. Versari D, Daghini E, Rodriguez-Porcel M, Sattler K, Galili O, Pilarczyk K, Napoli C, Lerman LO, Lerman A: Chronic antioxidant supplementation impairs coronary endothelial function and myocardial perfusion in normal pigs. Hypertension 2006; 47: 475-481.